Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Summary

Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to severe psoriasis.

Timeline

Start

2012-04

Primary completion

2013-10

Completion

2014-05

Publications

• Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. Clin Pharmacokinet. 2019 Oct;58(10):1309-1321. doi: 10.1007/s40262-019-00759-z.

Drugs

Indications